Newsmeme!
Discover News you didn't know existed
A new study reveals that specific types of bacteria in the intestine trigger the generation of pro-inflammatory immune cells, a finding that could eventually lead to novel treatments for inflammatory bowel disease and other diseases.
NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that four abstracts summarizing data from the Company's Phase 3 studies of GATTEX(TM) (teduglutide) in patients with short bowel syndrome (SBS) were selected for oral presentations at the 16th United European Gastroenterology Week (UEGW) meeting in Vienna, Austria, October 18-22, 2008, including a presentation of 52-week data from the ...
BEDMINSTER, N.J.----NPS Pharmaceuticals, Inc. today announced that four abstracts summarizing data from the Company's Phase 3 studies of GATTEX™ in patients with short bowel syndrome were selected for oral presentations at the 16th United European Gastroenterology Week meeting in Vienna, Austria, October 18-22, 2008, including a presentation of 52-week data from the Phase 3 study of GATTEX in ...
The wife of Leeds United legend Lucas Radebe has been remembered at a memorial service in South Africa following her death from bowel cancer. (15/10/2008 14:21:36)
Almost 100 patients in Somerset who were tested for bowel conditions could face further tests following doubts over how well the examinations were carried out.
Kearny students and staff worked together to raise money for ovarian cancer research. The children of Kearny, the school staff/faculty and retired faculty raised $10,021.
Changing the approach to genetic screening for cancers in Australia could effectively halve deaths caused by an inherited form of bowel cancer, says a University of Melbourne expert.
Flaxseed has been a part of human and animal diet for thousands of years. Flaxseed is eaten for its health benefits and has gained popularity [...]
Small body movements that occur while breathing are enough to cause unnecessary damage to healthy tissue when treating cancerous tumours with radiotherapy, but a unique solution has been invented by a QUT professor.
ChemoCentryx, Inc., announced today that it has initiated a Phase I clinical trial of CCX025, the company's fourth investigational new drug and second orally administered compound that inhibits the chemokine receptor known as CCR9.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |